Clinical trial · Observational
Development and Validation of Nomogram Predicting Survival in Chinese SCLC Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this retrospective study, patients diagnosed with SCLC between January 2011 to September 2022 were identified from database of the Second Hospital of Shandong University. Following inclusion criteria should be met: (1) Had histologically or cytologically confirmed newly diagnosed SCLC; (2) No cancer treatment has been done before; (3) Complete clinical, laboratory, imaging, treatment data and follow-up information. The exclusion criteria included: Patients without complete records for pathological information, complete epidemiology and other key clinical information.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| initial chemotherapy response | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- training cohort
- description
- The investigators used the training cohort to develop the predictive nomogram with potential risk factors( initial response to chemotherapy)
- interventionNames
- Other: initial chemotherapy response
- label
- validation cohort
- description
- The investigators used the validation cohort to verify the clinical utility and predictive ability
- interventionNames
- Other: initial chemotherapy response
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- January 2011 to September 2022
- description
- the Time Between the Discovery of the Tumor and the Patient's Death
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Newly diagnosis of small cell lung cancer 2. No cancer treatment has been done before 3. Complete clinical, laboratory, imaging, treatment data and follow-up information Exclusion Criteria: 1\. Without complete records for pathological information, complete epidemiology and other key clinical information
References
Publications (1)
- BACKGROUNDLara PN Jr, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR; Southwest Oncology Group. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008 Jan 20;26(3):463-7. doi: 10.1200/JCO.2007.13.0344. PMID 18202421